

Answer : LANXESS has a specific disinfectant Rely+On™ Virkon™, for the areas associated with Human Health, which is available through the specialist partners who support the Human Health industry, in each country where the product is registered.

Rely+On™ Virkon™ was widely used during the SARS challenges, the MERS (both coronaviruses) outbreak of 2015 in Saudi Arabia and South Korea, as well as to assist overcome the Norovirus in South Korea during the Olympic games.



Coronavirus Middle East Resp. Syndrome (MERS)	ATCC VR-740	1:100
---	-------------	-------

The efficacy data supports Rely+On™ Virkon™ to inactivate Coronavirus associated with the human outbreaks.

The exact strain of virus is highly critical to develop medication and vaccines. It is good news that the virus is now already replicated in Australia, where dynamic work will continue to support treatment and prevention remedies.

It is true to note that Virkon™ S also has efficacy against coronaviruses, as these viruses cross over species, with mammals and birds often affected. The associated coronaviruses with the Virkon™ S efficacy are noted in the table below: The proven efficacy is across a wide range of temperature >

Coronaviridae	Coronavirus	Infectious Bronchitis Virus	131	AOAC standard	USA	EPA	1:100
	Coronavirus	TGE Virus	8	Strain FS216/63	England	DEFRA method	1:450
	Coronavirus	TGE Virus	71	ATCC VR-763	USA	EPA	1:100
	Coronavirus	Feline infectious Peritonitis	172	ATCC VR2202	USA	EPA	1:100
	Coronavirus	Canine Coronavirus	175	ATCC VR-809	USA	EPA	1:100
	Coronavirus	Infectious bronchitis	248	Solvay AH strain Beaudette IB42	USA	EPA	1:100
	Coronavirus	Porcine enteric diarrhoea virus	255	Colorado 2013 isolate	USA	EPA	1:800
	Coronavirus	Infectious Bronchitis Virus	262	Solvay AH strain Beaudette IB42	USA	EPA	1:200
	Coronavirus	Porcine enteric diarrhoea virus	269	Colorado 2013 isolate	USA	EPA	1:200

With the similarities of the main biocide activity of Virkon™ S when compared to the Rely+On™ Virkon™, it is expected that Virkon™ S would inactivate the virus in areas around and outside the Human Health 'spaces' when applied at guided dilution rates. If such application were thought necessary for barrier controls, for example, or areas outside of medical institutions and associated 'places of care', then we would suggest to default to a 1%, or 0.5% (1 to 100 or 1 to 200) dilution for Virkon™ S.

LANXESS will continue to invest with additional efficacy data, as soon as the current virus strain is available for such tests.

Anthony Pearson
Head Technical Marketing for BioSecurity and Hygiene
ACD,MPP
29.01.2020

LANXESS
Energizing Chemistry

Antec International Ltd.
Windham Rd, Chilton Ind. Est.
Sudbury, Suffolk, CO10 2XD
United Kingdom.

www.virkon.com
biosecurity@lanxess.com

All rights reserved.

The information set forth herein is furnished free of charge and based on technical data that LANXESS believes to be reliable. It is intended for use by persons having technical skill, at their own risk. Because conditions of use are outside our control, LANXESS makes no warranties, expressed or implied, and assumes no liability in connection with any use of this information. Nothing herein is to be taken as a license to operate under, or a recommendation to infringe, any patents or patent applications.

The specified uses and registered claims for the product/s™ may vary from country to country. Please contact LANXESS directly to verify country-specific approved usages.

Use biocides safely. Always read the label and product information before use.

©2019 LANXESS. Virkon™ and any associated logos are trademarks or copyrights of LANXESS Corporation. LANXESS™ and the LANXESS Logo are trademarks of LANXESS Deutschland GmbH. All trademarks are registered in many countries worldwide.